THE U.S. GOVERNMENT ACCOUNTABILITY OFFICE APPOINTS COEUS’ DOUG BROWN TO MACPAC.
DOUG BROWN, SENIOR VICE PRESIDENT OF VALUE AND ACCESS, COEUS, APPOINTED BY THE GOVERNMENT ACCOUNTABILITY OFFICE TO THE MEDICAID AND CHIP PAYMENT AND ACCESS COMMISSION (MACPAC)
Brown is One of Two New Appointees Who Will Serve Through 2027
DEVON, PA (May 8, 2024)— COEUS is pleased to announce that Doug Brown, the company’s Senior Vice President of Value and Access, has been appointed to the Medicaid and CHIP Payment and Access Commission (MACPAC). Brown is one of two new appointees, four reappointments, and one Vice Chairman named today by Gene L. Dodaro, Comptroller General of the United States and head of the U.S. Government Accountability Office (GAO).
“The men and women who serve on this commission bring an impressive level of knowledge and experience to advise Congress on Medicaid and the Children’s Health Insurance Program,” Dodaro said. “I am very pleased to announce today’s two new appointments, four reappointments, as well as the naming of the new Chair.”
Brown and his newly appointed co-member, Michael Nardone, will serve until their current term expires in April 2027. Current members Heidi Allen, Robert Duncan, Verlon Johnson, and John McCarthy were reappointed to new terms, which will also expire in April 2027. Verlon Johnson has also been named the Commission’s Chair, and Robert Duncan will continue as the Vice Chair.
“I’m honored to be appointed by GAO to serve as a MACPAC Commissioner,” stated Brown. “It’s a privilege to serve the non-partisan legislative branch agency that provides policy and data analysis and makes recommendations to Congress, the Secretary of the U.S. Department of Health and Human Services, and the states on a wide array of issues affecting Medicaid and the State Children’s Health Insurance Program (CHIP). I look forward to working closely with the MACPAC staff and my fellow Commissioners to ensure that Medicaid and CHIP policy evolves to meet the current and future needs of each program and the millions of people they serve.”
The Children’s Health Insurance Program (CHIP) Reauthorization Act of 2009 established MACPAC to review Medicaid and CHIP access and payment policies and to advise Congress on issues affecting Medicaid and CHIP. The Act directs the Comptroller General to appoint MACPAC’s members.
Doug Brown, RPh, MBA, is Senior Vice President of Value and Access at COEUS, with over 30 years of pharmacy management experience. Mr. Brown provides executive-level healthcare consulting and market access support services to life science companies and healthcare organizations, including the development of value- and outcomes-based contracting strategies with state Medicaid programs, pharmacy benefit administrators, manufacturers, and the Centers for Medicare & Medicaid Services. Prior to joining COEUS in 2020, he served in several roles for Magellan Rx Government, including as the Chief Strategy Officer. While at Magellan, he led preferred drug list management for more than half the state Medicaid programs in the country, provided subject matter expertise on federal and state government legislation that impacted state Medicaid programs, and offered policymakers a national view of evolving events in Medicaid. Mr. Brown is a registered pharmacist and holds a Bachelor of Science in pharmacy from the University of Rhode Island and a Master of Business Administration from Virginia Commonwealth University.
About COEUS
Established in 2009, COEUS is a leading healthcare consulting, communications, technology, and talent firm. The company offers clients a variety of services, as well as SaaS technology platforms, for various stakeholders throughout the healthcare ecosystem including all payers and emerging or more established drug manufacturers. Leveraging the deep knowledge and experience of the company’s many subject matter experts, COEUS works on all drug types with a particular focus on cell and gene therapies, rare diseases, and oncology. The company also has unique expertise in the creation and management of value-based agreements by leveraging COEBRA™, the company’s evidence and outcomes adjudication platform. In its 15-year history, the company has supported the launch of more than 130 pharmaceutical brands and has worked with more than 300 pharma clients including many top global pharmaceutical manufacturers. To learn more about COEUS and the company’s offerings, visit 1COEUS.com.
